Shift Pharmaceuticals Holdings, Inc.
Columbia, MO Impedx Diagnostics
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- shiftpharmaceuticals.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| 3P Biotechnologies, Inc. | Prospect, KY | 541713 Research and Development in Nanotechnology |
| Biostrategies LC | Jonesboro, AR | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Human Cell Co | Naperville, IL | — |
| Acepre, LLC | Columbia, SC | 325412 Pharmaceutical Preparation Manufacturing |
| Lucerna Inc. | Los Angeles, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Shift Pharmaceuticals Holdings, Inc., registered in SAM.gov since May 16, 2019, is a for-profit corporate entity located in Columbia, Missouri, specializing in developing advanced antisense oligonucleotide (ASO) therapeutics targeting complex genetic and neurological disorders. The company focuses on innovative pharmaceutical research and development, with a particular emphasis on creating targeted molecular therapies that address genetic diseases through precise genetic intervention strategies. Through its Impedx Diagnostics Division, Shift Pharmaceuticals demonstrates a sophisticated approach to developing cutting-edge medical treatments that target specific genetic mechanisms underlying various challenging medical conditions.
The company has secured multiple federal grants from the National Institute of Neurological Disorders and Stroke and the National Eye Institute, focusing on developing specialized antisense oligonucleotide therapies for complex medical conditions. Specifically, Shift Pharmaceuticals has pursued grant-funded research in three key areas: developing an ASO therapeutic for Spinal Muscular Atrophy (SMA) with a lead candidate (E1V1.11) that shows significant improvements in animal model survival rates, creating targeted therapies for Charcot-Marie-Tooth disease type 1A (CMT1A) by modulating PMP22 protein production, and designing ASO inhibitors to mitigate vision loss in retinitis pigmentosa and age-related macular degeneration by targeting retinoic acid signaling. These research projects demonstrate the company's sophisticated approach to developing precision molecular therapies that can potentially address critical unmet medical needs through advanced genetic intervention strategies.
Quick answers
Is Shift Pharmaceuticals Holdings, Inc. registered in SAM.gov?
Yes. Shift Pharmaceuticals Holdings, Inc.'s SAM.gov registration is active through August 31, 2027.
What is Shift Pharmaceuticals Holdings, Inc.'s CAGE code?
Shift Pharmaceuticals Holdings, Inc.'s CAGE code is 7TJM2, and its Unique Entity ID (UEI) is L5YJHR8PKA96.
What is Shift Pharmaceuticals Holdings, Inc.'s most recent federal award?
Shift Pharmaceuticals Holdings, Inc.'s most recent federal grant award is Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating… (R41EY036319), from National Eye Institute (NIH), on August 1, 2025.
On GovTribe
See Shift Pharmaceuticals Holdings, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors